Key Dates

Related Announcements

PAR-22-112 - Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required)

Issued by

National Institute of Mental Health (NIMH)

Purpose

The purpose of this Notice is to alert potential applicants of the following change to PAR-22-112 “Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required).” The changes in the PAR updated the areas of high priority for HIV/AIDS Research. Applications submitted to this Funding Opportunity Announcement must aim to address urgent, time-sensitive mental health research questions related to COVID-19, including broader secondary impacts of the pandemic as well as research on the intersection of mental health, COVID-19, and HIV.

Section I. Funding Opportunity Description of PAR-22-112 has been modified as follows:

Currently reads:

Areas of High Program Priority

HIV/AIDS Research

• Clinical trials of communication strategies to address HIV and SARS-CoV-2 testing and vaccine hesitancy, to enhance SARS-CoV-2 vaccination series initiation, completion and booster follow-up as recommended for people living with HIV or populations with a high HIV incidence.
• Clinical trials of community approaches for effective information dissemination related to HIV/SARS-CoV-2 screening that apply strengths-based approaches to community engagement and frameworks that emphasize resilience, empowerment, positive reflections and amplify the voices of communities placed at risk that result in increased uptake of screening and linkage to care.
• Research to promote HIV self-testing and SARS-CoV-2 self-testing including use of digital technologies, supports, or innovative strategies (e.g., secondary distribution, or communications-based) to increase frequency and timeliness of return of results, confirmatory or regular testing, contact tracing and linkage to ongoing HIV and COVID-19 prevention or treatment services.
• Clinical trials of programs that integrate SARS-CoV-2 testing with HIV testing or other screenings, or which leverage existing HIV testing programs, strategies, and initiatives to expand access to and increase SARS-CoV-2 testing in marginalized communities.
• Clinical trials to address CNS complications of COVID-19 in people living with HIV that aim to test evidence-based therapeutic interventions.
• Clinical trials of interventions such as those conducted through telemedicine that promote continuity of HIV prevention and care services, including mental health services, during the COVID-19 pandemic particularly for populations experiencing health disparities.
• Clinical trials of interventions such as those conducted through telemedicine that promote continuity of HIV prevention and care services, including mental health services, during the COVID-19 pandemic particularly for populations experiencing health disparities.
• Studies testing implementation strategies to promote uptake of evidence-based interventions to address HIV-related prevention and care needs as they relate to the COVID-19 pandemic, such as interventions designed to strengthen infrastructure and streamline procedures for integrated HIV and SARS-CoV-2 testing programs, community-based interventions to encourage integrated HIV and SARS-CoV-2 self-testing in relevant populations, and telemedicine to address COVID-19-related barriers to HIV prevention and care continuity, such as social distance measures.

Modified to Read:

Areas of High Program Priority

HIV/AIDS Research

• Clinical trials of interventions such as those conducted through telemedicine that promote continuity of HIV prevention and care services, with an emphasis on mental health services, during the COVID-19 pandemic particularly for populations experiencing health disparities.
• Clinical trials testing implementation strategies to promote uptake of evidence-based interventions to address COVID-19 impacts on mental health in individuals living with HIV.
• Clinical trials of interventions such as those conducted through telemedicine that promote continuity mental health services in individuals living with HIV during the COVID-19 pandemic particularly for populations experiencing health disparities.
• Clinical trials to address CNS complications of COVID-19 in people living with HIV that aim to test evidence-based therapeutic interventions.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Division of AIDS Research

Pim Brouwers, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 240-627-3863
Email: [email protected]

Division of Neuroscience and Basic Behavioral Science

Susan Koester, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-3563
Email: [email protected]

Division of Services and Intervention Research

Adam Haim, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-435-3593
Email: [email protected]

Division of Translational Research

Susan Borja, Ph.D.
National Institute of Mental Health (NIMH)
Telephone: 301-443-1252
Email: [email protected]

Center for Global Mental Health Research

Leonardo Cubillos, M.D. M.Ph.
National Institute of Mental Health (NIMH)
Telephone: 301-827-9095
Email: [email protected]v

Office for Disparities Research and Workforce Diversity (ODWD)

Dawn Morales Ph.D.
National Institutes of Mental Health (NIMH)
Telephone: 301-827-9668
Email: [email protected]